Welcome to our dedicated page for Tenaya Therapeutics news (Ticker: TNYA), a resource for investors and traders seeking the latest updates and insights on Tenaya Therapeutics stock.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) is a clinical-stage biotechnology company focused on discovering, developing and delivering potentially curative therapies that address the underlying drivers of heart disease. The Tenaya Therapeutics news feed highlights company announcements, clinical data updates and financial disclosures related to its gene therapy and small molecule programs for genetic cardiomyopathies and heart failure.
News about Tenaya frequently centers on TN-201, its AAV9-based gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), and TN-401, its AAV9-based gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Company press releases provide interim safety, biopsy and early efficacy results from the MyPEAK-1 and RIDGE-1 Phase 1b/2 clinical trials, including observations on protein expression, arrhythmia measures and biomarkers.
Investors and followers of TNYA can also find updates on regulatory interactions, such as FDA designations and clinical hold communications, as well as information on Tenaya’s capital-raising activities through public offerings described in SEC filings and related press releases. Additional news items cover participation in scientific and investor conferences, late-breaking presentations at major cardiology and gene therapy meetings, and publications that describe Tenaya’s research platforms and preclinical findings.
This page aggregates these disclosures so readers can review Tenaya Therapeutics’ latest reported milestones, from clinical trial progress for TN-201 and TN-401 to developments in its broader pipeline, including the TN-301 small molecule HDAC6 inhibitor and early-stage preclinical programs. For those tracking TNYA, the news stream offers a consolidated view of how the company reports advancing its mission to address genetic drivers of heart disease.
Tenaya Therapeutics, a biotechnology firm, reported significant advancements in its gene therapy programs and third quarter 2021 financial results. The company initiated a global natural history study for children with MYBPC3 mutations to enhance the TN-201 gene therapy development. Preclinical data demonstrated promising outcomes in murine models, highlighting durability in disease reversal. Tenaya's cash position stands strong at $280.5 million post-IPO, expected to sustain operations through late 2023. Despite a net loss of $18.3 million, the company continues its progress towards clinical-stage development.
Summary not available.
Tenaya Therapeutics (NASDAQ: TNYA) announced that CEO Faraz Ali will participate in multiple key biotechnology conferences in October. Events include the Chardan 5th Annual Genetic Medicines Conference on October 4, featuring a panel discussion and a fireside chat. Ali will also speak at the Alliance for Regenerative Medicine’s Cell and Gene Meeting on October 13, followed by a company presentation. Lastly, he will present at the Jefferies Gene Therapy/Editing Summit on October 28. Tenaya focuses on innovative therapies for heart disease.
Tenaya Therapeutics (TNYA) announced significant developments, including the granting of Orphan Drug Designation for its TN-201 gene therapy for genetic HCM by the FDA. The company successfully completed its IPO on August 3, 2021, raising $207 million. Leadership changes include Leone Patterson as Chief Financial Officer and Matt Pollman as SVP of Clinical Development. Financial results for Q2 2021 show a net loss of $15.2 million and R&D expenses of $10.9 million. Tenaya anticipates submitting IND applications for TN-201 and TYA-11631 in 2022.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology firm focused on heart disease therapies, announced that CEO Faraz Ali will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 10 at 2:45 p.m. ET. The company's mission is to develop curative therapies addressing heart disease's underlying causes through gene therapy, cellular regeneration, and precision medicine. Founded by top cardiovascular scientists, Tenaya aims to tackle both rare genetic disorders and more common heart conditions.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) has successfully closed its upsized initial public offering, selling 13,800,000 shares at $15.00 each, totaling gross proceeds of $207.0 million. This offering included the full exercise of underwriters' options for 1,800,000 additional shares. Shares began trading on the Nasdaq Global Select Market on July 30, 2021. Morgan Stanley, Cowen, and Piper Sandler served as joint book-running managers, with Chardan leading the offering. The registration statements for this IPO were effective as of July 29, 2021.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) has announced the pricing of its upsized initial public offering (IPO) of 12 million shares at $15.00 each, set to trade on the Nasdaq from July 30, 2021. The IPO is expected to generate gross proceeds of $180 million, with an option for underwriters to purchase an additional 1.8 million shares. The offering closes on August 3, 2021, pending usual conditions, with Morgan Stanley, Cowen, and Piper Sandler as joint book-running managers. Tenaya aims to develop therapies for heart disease, leveraging expertise from top scientific institutions.